Yes, Iovance's results ARE impressive. At the time, Advaxis' results were impressive. If they used the same exclusions that Iovance used, they may have seen even better. It will also come down to cost issues, side effects, quality of life, etc. You are correct in that the delays, stops and starts and a lack of focus have pushed Advaxis out of the forefront when they had a clear advantage. If they DO get an earlier interim analysis then they MIGHT be able to go for an accelerated approval if the results are very good. They are in a PIII so I don't think we're still at square one but it sure feels like it. I'm not disputing anything you say, I'm just hoping that we can get to the finish line first.
News 
Market Data 
Discover 
AI
